|Bid||3.0600 x 2200|
|Ask||3.1000 x 1400|
|Day's Range||3.0900 - 3.3500|
|52 Week Range||0.9500 - 9.9000|
|Beta (5Y Monthly)||2.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the Company’s first-in-class, off-the-shelf CD16-targeted natural killer (haNK) cells in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
If you want to know who really controls NantKwest, Inc. (NASDAQ:NK), then you'll have to look at the makeup of its...
NantKwest, Inc. (NASDAQ:NK) shareholders should be happy to see the share price up 11% in the last month. But only the...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2015 Patrick Soon-Shiong was appointed CEO of NantKwest, Inc.Read More...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...